Clinical Trials Logo

Clinical Trial Summary

The objective of this study is to evaluate the efficacy and safety of a fractional 1,064 nm picosecond laser for the treatment of striae alba.


Clinical Trial Description

Striae distensae are atrophic dermal scars that can cause psychosocial distress on affected patients. Despite numerous available therapeutic modalities, no gold standard therapy has been established. Picosecond lasers are a newer advancement in lasers that have primarily used in the treatment of tattoos. A fractional 1064-nm picosecond laser has recently become available for the treatment of pigmentation and skin rejuvenation. The main mechanism of action is tissue ablation via laser induced optical breakdown (LIOB) which occur when pulse intensity is high enough to strip electrons and generating plasma, the plasma absorbs the remaining laser energy forming a cavitation bubble within the dermis which has been demonstrated to improve fine wrinkles and acne scar through the stimulation of collagen formation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04456257
Study type Interventional
Source Mahidol University
Contact Woraphong Manuskiatti, M.D.
Phone +66819150555
Email doctorlaser@gmail.com
Status Recruiting
Phase N/A
Start date May 1, 2020
Completion date December 30, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04092881 - Efficacy of Short Pulsed 1064 nm Nd-YAG Laser Versus 10600 nm Fractional CO2 Laser in Treatment of Striae Alba N/A